Prof. Chaim Putterman

עברית Tell a Friend
Associate Dean, Research
Telephone
Bar-Ilan Email
chaim.putterman@biu.ac.il
Office
chaim.putterman@biu.ac.il
Academic field
Immunology
Research field
Cellular and Molecular Autoimmunity
Research Center
Galilee Medical Center, Nahariya
Hospital
Galilee Medical Center, Nahariya
CV

Dr. Putterman is Professor and Associate Dean for Research at the Azrieli Faculty of Medicine of Bar-Ilan University (Zefat, Israel), and Director of the Research Institute at Galilee Medical Center (Nahariya, Israel). In addition, Dr. Putterman serves as Professor of Medicine and Microbiology & Immunology at the Albert Einstein College of Medicine and Montefiore Medical Center (Bronx, New York). Dr. Putterman’s major research interests are in the field of immunology and autoimmune diseases, and specifically the identification and characterization of novel mechanisms, biomarkers, and treatment approaches to immune mediated nephritis, neuropsychiatric lupus, and systemic lupus erythematosus. 

Dr. Putterman’s laboratory has received funding from the National Institute of Health, Alliance for Lupus Research, Lupus Research Institute, Arthritis Foundation, Boehringer Ingelheim, and Biogen Idec, and he has published more than 200 articles and book chapters in the medical and scientific literature. He was elected to the American Society of Clinical Investigation, and is a member of the American College of Rheumatology and the American Association of Immunologists. Dr. Putterman has served on multiple NIH and international study sections, and is currently a member of several editorial boards.

Publications
  1. and west. Autoimmunity Rev 16:1175-1184, 2017.  
  2. Broder A, Mowrey WB, Khanm HN, Jovanovic, B, Londono-Jimenez A, Izmirly P, Putterman C. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Seminars Arth Rheum 47:545-551, 2018.   
  3. Chalmers SA, Wen J, Doerner E, Stock A, Cuda CM, Makindeb HM, Perlman H, Bosanac T, Webb D, Nabozny G, Fine JS, Klein E, Ramanujam M, Putterman C. Highly selective inhibition of Bruton’s tyrosine kinase attenuates skin and brain disease in murine lupus. Arth Res Ther 25;20:10. doi: 10.1186/s13075-017-1500-0, 2018.   
  4. Xia Y, Eryilmaz E, Cowburn D, Putterman C. Structure-function in antibodies to double stranded DNA. In: Almo S, Cowburn D, Putterman C (eds). Structural Biology in Immunology: Structure and Function of Novel Molecules of Immunologic Importance. 1st Edition. Academic Press (Elsevier), London, UK, pg. 127-144, 2018.  
  5. Stock A, Putterman C. The pathogenesis of lupus affecting the central nervous system. In: Dubios’ Systemic Lupus Erythematosus, 8th edition, 2018.  
  6. Jain S, Stock A, Macian F, Putterman C. A distinct T follicular helper cell subset infiltrates the brain in lupus associated neuropsychiatric disease. Front Immunol  https://doi.org/10.3389/fimmu.2018.00487, 2018.  
  7.   Gelb S, Stock AD, Anzi S, Putterman C, Ben-Zvi A. Mechanisms of neuropsychiatric lupus: the relative roles of the blood-CSF versus blood-brain barrier. J Autoimmunity 91:34-44, 2018.   
  8. Merrill JT, Petri MA, Buyon J, Ramsey-Goldman R, Kalunian K, Putterman C, Conklin J, Furie RA, Dervieux T. Erythrocyte bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science & Medicine 2018;5:e000263. doi:10.1136/lupus-2018-000263 
  9.      Londono Jimenez Alejandra, Wenzhu M, Putterman C, Buyon J, Goilav B, Broder A. Tubulointerstitial damage in lupus nephritis: a comparison of the factors associated with tubulointerstitial inflammation and renal scarring. Arthritis Rheum 70:1801-1806, 2018.  
  10.      Mike EV, Makinde HM, Der E, Stock A, Gulinello M, Gadhvi GT, Winter DR, Cuda CM, Putterman C. Neuropsychiatric systemic lupus erythematosus is dependent on sphingosine-1-phosphate signaling. Front Immunol 2018 Sep 26;9:2189. doi: 10.3389/fimmu.2018.02189.  
  11. Putterman C, Pisetsky DS, Petri M, Caricchio R, Wu AHB, Sanz I, Oates JC, Wallace S, Sorek R, Gerwien R, Safer P, Jakobi-Brook K, Cohen IR. The SLE-key test serological signature: new insights into the course of lupus. Rheumatology 57:1632-1640, 2018.  
  12.   Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Clin Immunol 197:205-218, 2018.  
  13.   Lauvsnes MB, Tjensvoll AB, Maroni SS, Kvivik I, Grimstad T, Greve OJ, Harboe E, Gøransson LG, Putterman C, Omdal R. The blood-brain barrier, TWEAK, and neuropsychiatric involvement in human systemic lupus erythematosus and primary Sjögren's syndrome. Lupus 27:2101-2111, 2018.  
  14. Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nature Reviews Rheumatology 15:137-152, 2019.  
  15.   Mike EV, Makinde HM, Gulinello M, Vanarsa K, Herlitz L, Gadhvi G, Winter DR, Mohan C, Hanly JG, Mok CC, Cuda CM, Putterman C. Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus. J Autoimmunity 96:59-73, 2019.  
  16. Der E, Suryawanshi H, Buyon J, Tuschl T, Putterman C. Single-cell RNA sequencing for the study of lupus nephritis.Lupus Sci Med. 4; 6(1):e000329. doi: 10.1136/lupus-2019-000329, 2019.   
  17.   Chalmers SA, Garcia SJ, Reynolds JA, Herlitz L, Putterman C. NF-kB signaling in myeloid cells mediates the pathogenesis of immune-mediated nephritis. J Autoimmunity 98:33-43, 2019.  
  18.   Izmirly P, Buyon J, Wan I, Belmont H, Sahl S, Salmon JE, Askanase A, Bathon J, Geraldino L, Ali Y, Ginzler E, Putterman C, Gordon C, Helmick C, Parton H. The incidence and prevalence of adult primary Sjögren’s syndrome in New York county. Arthritis Care Res 71:949-960, 2019.   
  19.   Stohl W, Yu N. Chalmers SA, Putterman C, Jacob CO. Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate systemic lupus erythematosus in NZM 2328 mice. Lupus Sci Med 6:e000313. doi:10.1136/lupus-2018-000313, 2019.  
  20.   Smith EMD, Eleuteri A, Goilav B, Lewandowski L, Phuti A, Rubinstein T, Wahezi D, Jones CA, Marks SD, Corkhill R, Pilkington C, Tullus K, Putterman C, Scott C, Fisher AC, Beresford MW. A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activity. Clin Immunol 198:71-78, 2019.  
  21.   Broder A, Mowrey WB, Golestaneh L, Putterman C, Costenbader KH, Kim M. Methodological considerations in comparing access to pre-emptive renal transplantation between SLE and other ESRD causes in the USRDS. Sem Arth Rheum 48:678-685, 2019. 
  22.   Das S, The Extracellular RNA Communication Consortium, Ansel KM, Bitzer M,  Breakefield XO, Charest A, Galas DJ, Gerstein MB, Gupta M, Milosavljevic A,  McManus MT, Patel T, Raffai RL, Rozowsky J, Roth ME, Saugstad JA, Van Keuren-Jensen K,  Weaver AM, Laurent LC. The Extracellular RNA Communication Consortium: establishing foundational knowledge and technologies for extracellular RNA research. Cell 177:231-237, 2019.    
  23.   Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby A, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall’Era M, Park M,  Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, the Accelerating Medicines Partnership in RA/SLE network, Hacohen N, Diamond B. The immune cell landscape in kidneys of lupus nephritis patients. Nature Immunology 20:902-914, 2019.   
  24. Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabathou S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, Mokrzycki M, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Accelerating Medicines Partnership in RA/SLE network, Buyon J, Tuschl T, Putterman C. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nature Immunology 20:915-927, 2019. (Editorial: Nature Immunology 20:777-778, 2019; Highlighed in Nature Reviews Nephrology (June 2019) and Nature Reviews Rheumatology (June 2019).  
  25.   Stock AD, Der E, Gelb S, Huang M, Weidenheim K, Ben-Zvi A, Putterman C. Choroid plexus tertiary lymphoid structures in lupus: a novel neuro-immune interface. J Clin Invest Insight 4 (11) pii: 124203. doi: 10.1172/jci.insight.124203, 2019.   
  26. Hoover P, Der E, Berthier CC, Arazi A, Lederer JA, James JA, Buyon J, Petri M, Belmont HM. Izmirly P, Hacohen N, Diamond B, Putterman C, Davidson A. The Accelerating Medicines Partnership: Organizational structure and preliminary data from the phase 1 studies of lupus nephritis. Arthritis Care Res 72:233-242, 2020.  
  27.   Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, Collins CE, Saxena A, Putterman C, Kalunian KC, O’Malley T, Dervieux T, Weinstein A. Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE. Arthritis Rheum 72:78-88, 2020. 
  28. Moore E, Huang M, Putterman C. Advances in the diagnosis, pathogenesis, and treatment of neuropsychiatric systemic lupus erythematosus. Curr Opin Rheum 32:152-158, 2020.  
  29.   Stohl W, Yu N, Chalmers S, Putterman C, Jacob CO. Development of murine systemic lupus erythematosus in the absence of BAFF. Arthritis Rheum 72:292-302, 2020.  
  30.   Makinde HM, Winter DR, Procissi D, Mike EV, Stock AD, Kando MJ, Gadhvi GT, Droho S, Bloomfield CL, Dominguez ST, Mayr MG, Lavine JA, Putterman C, Cuda CM. A novel microglia-specific transcriptional signature correlates with behavioral deficits in neuropsychiatric lupus. Front Immunol. 2020 Feb 26;11:230. doi: 10.3389/fimmu.2020.00230.   
  31.   Arriens C, Alexander RV, Narain S, Saxena A, Collins CE, Wallace DJ, Massarotti E, Conklin J, Kalunian KC, Putterman C, Ramsey-Goldman R, Buyon JP, Askanase A, Furie RA, James JA, Bello GA, Manzi S, Ahearn J, O'Malley T, Weinstein A, Dervieux T. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med. 2020 Apr;7(1):e000377. doi: 10.1136/lupus-2019-000377. 
  32. Oláh C, Schwartz N, Denton C, Kardos Z, Putterman C, Szekanecz Z. Cognitive dysfunction in autoimmune rheumatic diseases. Arthritis Res Ther. 2020 Apr 15;22(1):78. 
  33.   Stanley S, Vanarsa K, Soliman S, Habazi D, Pedroza C, Gidley G, Zhang T, Mohan S, Der E, Suryawanshi H, Tuschl T, Buyon J, Putterman C, Mok CC, Petri M, Saxena R, Mohan C. Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. Nat Commun. 2020 May 4;11(1):2197. doi: 10.1038/s41467-020-15986-3. 
  34. Moore E, Putterman C. Are lupus animal models useful for understanding and developing new therapies for human SLE? J Autoimmun 2020 Jun 10:102490. doi: 10.1016/j.jaut.2020.102490. Online ahead of print. 
  35. Ramanujama M, Steffgen J, Visvanathana S, Mohan C, Fine JS, Putterman C. Phoenix from the flames: Rediscovering the role of the CD40–CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmunity Rev (accepted for publication), 2020.  
  36. Vanarsa K, Henderson J, Soomro S, Qin L, Zhang T, Jordan N, Putterman C, Blanco I, Saxena R, Mohan C. Upregulation of proinflammatory bradykinin peptides in systemic lupus erythematosus and rheumatoid arthritis. J Immunol. 2020 Jun 15:ji1801167. doi: 10.4049/jimmunol.1801167.  
  37. Moore E, Huang M, Macian M, Putterman C. The T cell receptor repertoire in
    neuropsychiatric systemic lupus erythematosus. Frontiers in Immunology (in press), 2020. 
Media

https://www.google.com/search?rlz=1C1SKPM_enIL404IL404&biw=1094&bih=506&tbm=nws&ei=r9TpX5TdEqq61fAPlPm3oAE&q=chaim+putterman&oq=chaim+putterman&gs_l=psy-ab.12...6748.7646.0.11080.6.6.0.0.0.0.153.418.0j3.3.0....0...1c.1.64.psy-ab..3.0.0....0.y0lBNBF87qE

 

https://worldisraelnews.com/watch-corona-wont-disappear-without-vast-majority-vaccinated-says-israeli-professor/

 

https://www.facebook.com/iltvisraelnews/posts/2695953980655843

 

https://www.jpost.com/health-science/coronavirus-did-not-go-away-in-the-summer-heres-what-we-know-638242

 

https://themedialine.org/people/with-attention-on-covid-other-diseases-take-back-seat/

 

תמונה 1

With Attention on COVID, Other Diseases Take Back Seat - The Media Line

Duplicated research and stretched budgets stall progress on other medical conditions. With 19,300 active cases in the Jewish state, the best and the brightest Israeli minds are furiously seeking a cure or treatment for the novel coronavirus.

themedialine.org

 

תמונה 2

Coronavirus did not go away in the summer – here’s what we know - The Jerusalem Post

Coronavirus did not go away in the summer – here’s what we know To date, some of the world’s hottest countries - Brazil and Saudi Arabia, for example - have had the largest outbreaks.

www.jpost.com

 

 

ILTV - ILTV Insider - The cost of health - Sep. 1, 2020 | Facebook

ILTV Insider - The cost of health - Sep. 1, 2020. Your News From Israel- Sept.10, 2020 To lockdown or not to lockdown..., that is the question.Ministers grapple with the upcoming high holidays..

www.facebook.com

 

 

תמונה 3

WATCH: Corona won't disappear without vast majority vaccinated, says Israeli professor

worldisraelnews.com

 

https://www.ynet.co.il/articles/0,7340,L-5708792,00.html

http://www.gmc.org.il/?CategoryID=492&ArticleID=2814

Last Updated Date : 28/12/2020